新型抗凝药物：外科医生的观点。

The novel anticoagulants: the surgeons' prospective.

机构信息

Division of Cardiovascular Diseases, Department of Medicine, Mayo Clinic, Scottsdale, AZ 85259, USA.

出版信息

Surgery. 2013 Mar;153(3):303-7. doi: 10.1016/j.surg.2012.09.016. Epub 2012 Dec 4.

DOI:10.1016/j.surg.2012.09.016

Abstract

Anticoagulants can complicate the approach to the management of patients undergoing operative interventions. We review new anticoagulants that have been introduced recently to the market or that are undergoing investigations for treatment of nonvalvular atrial fibrillation and venous thromboembolism prophylaxis: Dabigatran, rivaroxaban, apixiban, and edoxaban.

摘要

抗凝剂可能会使正在接受手术干预的患者的治疗方法变得复杂。我们回顾了最近新引入市场或正在研究用于治疗非瓣膜性心房颤动和静脉血栓栓塞预防的新型抗凝剂：达比加群、利伐沙班、阿哌沙班和依度沙班。